A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lombardi, 2018, Hepatocarcinoma: Genetic and epigenetic features, Minerva Gastroenterol Dietol, 64, 14
El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061
Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516
Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086
Bruix, 2011, Management of hepatocellular carcinoma: An update, Hepatology, 53, 1020, 10.1002/hep.24199
Raoul, 1992, Chemoembolization of hepatocellular carcinomas.A study of the biodistribution and pharmacokinetics of doxorubicin, Cancer, 70, 585, 10.1002/1097-0142(19920801)70:3<585::AID-CNCR2820700308>3.0.CO;2-#
Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156
Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X
Chen, 2016, Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis, Clin Res Hepatol Gastroenterol, 40, 309, 10.1016/j.clinre.2015.07.008
Bargellini, 2014, Trends in utilization of transarterial treatments for hepatocellular carcinoma: Results of a survey by the Italian Society of Interventional Radiology, Cardiovasc Intervent Radiol, 37, 438, 10.1007/s00270-013-0656-5
Martin, 2012, Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: A systematic review, Hepatogastroenterology, 59, 255
Cheung, 2016, Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma, Hepatobiliary Pancreat Dis Int, 15, 493, 10.1016/S1499-3872(16)60133-9
Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads.Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016/j.jhep.2012.01.008
Wiggermann, 2011, Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs.TACE with cisplatin/lipiodol (cTACE), Med Sci Monit, 17, CR189, 10.12659/MSM.881714
Arabi, 2015, Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma, Saudi J Gastroenterol, 21, 175, 10.4103/1319-3767.157571
Ou, 2019, Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma, Clin Radiol, 74, 295, 10.1016/j.crad.2018.12.008
Gorodetski, 2017, Advanced-stage hepatocellular carcinoma with portal vein thrombosis: Conventional versus drug-eluting beads transcatheter arterial chemoembolization, Eur Radiol, 27, 526, 10.1007/s00330-016-4445-9
Lee, 2017, Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size, J Gastroenterol Hepatol, 32, 487, 10.1111/jgh.13501
Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs.conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 111, 255, 10.1038/bjc.2014.199
Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study, Cardiovasc Intervent Radiol, 33, 41, 10.1007/s00270-009-9711-7
Brown, 2016, Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone, J Clin Oncol, 34, 2046, 10.1200/JCO.2015.64.0821
Sacco, 2011, Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma, J Vasc Interv Radiol, 22, 1545, 10.1016/j.jvir.2011.07.002
Malagari, 2010, Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma, Cardiovasc Intervent Radiol, 33, 541, 10.1007/s00270-009-9750-0
van Malenstein, 2011, A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma, Onkologie, 34, 368, 10.1159/000329602
Adam, 2004, Regional treatment of metastasis: Surgery of colorectal liver metastases, Ann Oncol, 15 Suppl 4, iv103, 10.1093/annonc/mdh912
Douhara, 2017, Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization, Oncol Lett, 14, 3028, 10.3892/ol.2017.6489
Poyanli, 2001, Palliative treatment of hepatocellular carcinoma by chemoembolization, Acta Radiol, 42, 602, 10.1080/028418501127347278
Liu, 2015, Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma, Korean J Radiol, 16, 125, 10.3348/kjr.2015.16.1.125
Norouzi, 2018, Crosstalk in cancer resistance and metastasis, Crit Rev Oncol Hematol, 132, 145, 10.1016/j.critrevonc.2018.09.017
Kloeckner, 2015, Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma, BMC Cancer, 15, 465, 10.1186/s12885-015-1480-x
Bai, 2018, Efficacy and safety of epirubicin applied in transcatheter arterial chemoembolization for hepatocellular carcinoma: A meta-analysis, J Cancer Res Ther, 14, 133, 10.4103/jcrt.JCRT_1261_16
Zhou, 2014, Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: A meta-analysis, Int J Clin Exp Med, 7, 3892